Seeking Alpha

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

RESEARCH TRIANGLE PARK, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (IRD) (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of inherited ...
Seeking Alpha

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

RESEARCH TRIANGLE PARK, N.C., May 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (IRD) (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of ...
Nasdaq

Opus Genetics, Inc. Announces Acceptance of Three Abstracts for Presentation at ARVO 2025 Meeting

Opus Genetics, Inc. announced that three abstracts concerning its investigational gene therapy candidates will be presented at the ARVO 2025 Meeting in Salt Lake City, UT, from May 4-8, 2025. The ...